Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab in Persistent or Chronic Primary ITP
NCT04200456Phase 3Terminated
- Sponsor
- UCB
- Start
- Jan 2020
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of rozanolixizumab in primary immune thrombocytopenia (ITP), sponsored by UCB. Started Jan 2020; status: terminated.
02
Drugs
rozanolixizumab
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04200456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04200456.